Agency Information Collection Activities: Submission for OMB Review; Comment Request, 18653-18655 [2024-05444]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 51 / Thursday, March 14, 2024 / Notices
Contact Person: Charlene J. Repique, Ph.D.,
Scientific Review Officer, Review Branch,
Division of Extramural Activities, NIDDK,
National Institutes Of Health, Room 7347,
6707 Democracy Boulevard, Bethesda, MD
20892–5452, (301) 451–3638,
charlene.repique@nih.gov.
This notice is being published less than 15
days prior to the meeting due to scheduling
difficulties.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: March 11, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–05435 Filed 3–13–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
ddrumheller on DSK120RN23PROD with NOTICES1
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–0361.
Proposed Project: New: The Center for
Substance Abuse Prevention Online
Reporting Tool and Grant
Programmatic Progress Report To
Replace Division of State Programs—
Management Reporting Tool (DSP–
MRT) (OMB No. 0930–0354)
The Substance Abuse and Mental
Health Services Administration’s
(SAMHSA), Center for Substance Abuse
Prevention (CSAP) is requesting
approval from the Office of Management
and Budget (OMB) to monitor CSAP
discretionary grant programs through
administration of a suite of data
collection instruments for grant
compliance and programmatic
performance monitoring. This package
describes the data collection activities
and proposed instruments. Grant
compliance monitoring will be
conducted via a single data collection
instrument to be completed by all CSAP
discretionary grant recipients.
Programmatic performance monitoring
VerDate Sep<11>2014
16:47 Mar 13, 2024
Jkt 262001
will be conducted via a suite of data
collection instruments with each
instrument tailored to a specific CSAP
discretionary program. This request for
data collection will replace OMB No.
0930–0354: Division of State
Programs—Management Reporting Tool.
CSAP intends to monitor six grant
programs through this data collection
effort:
• Strategic Prevention Framework—
Partnerships for Success (SPF–PFS): The
purpose of the SPF–PFS program is to
help reduce the onset and progression of
substance misuse and its related
problems by supporting the
development and delivery of state and
community substance misuse
prevention and mental health
promotion services. This program is
intended to promote substance use
prevention throughout a state
jurisdiction for individuals and families
by building and expanding the capacity
of local community prevention
providers to implement evidence-based
programs. In addition, the program is
intended to expand and strengthen the
capacity of local community prevention
providers to implement evidence-based
prevention programs. With this
program, SAMHSA aims to strengthen
state and community level prevention
capacity to identify and address local
substance use prevention concerns,
such as underage drinking, marijuana,
tobacco, electronic cigarettes, opioids,
methamphetamine, and heroin.
• Sober Truth on Preventing
Underage Drinking (STOP Act): The
purpose of this program is to prevent
and reduce alcohol use among youth
and young adults ages 12–20 in
communities throughout the United
States through evidence-based
screening, programs and curricula, brief
intervention strategies, consistent policy
enforcement, and environmental
changes that limit underage access to
alcohol as authorized by 942 U.S.C.
290bb–25b. The program aims to: (1)
address norms regarding alcohol use by
youth, (2) reduce opportunities for
underage drinking, (3) create changes in
underage drinking enforcement efforts,
(4) address penalties for underage use,
and/or (5) reduce negative consequences
associated with underage drinking.
• Strategic Prevention Framework for
Prescription Drugs (SPF Rx): The
purpose of the SPF Rx grant program is
to provide resources to help prevent and
address prescription drug misuse within
a State or locality. The program is
designed to raise awareness about the
dangers of sharing medications as well
as the risks of fake or counterfeit pills
purchased over social media or other
unknown sources, and work with
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
18653
pharmaceutical and medical
communities on the risks of
overprescribing. Whether addressed at
the state level or by an informed
community-based organization, the SPF
Rx program will raise community
awareness and bring prescription
substance misuse prevention activities
and education to schools, communities,
parents, prescribers, and their patients.
In addition, grant recipients will be
required to track reductions in opioid
related overdoses and incorporate
relevant prescription and overdose data
into strategic planning and future
programming.
• First Responders—Comprehensive
Addiction and Recovery Act (FR CARA):
The purpose of this program is to allow
first responders and members of other
key community sectors to administer a
drug or device approved or cleared
under the Federal Food, Drug, and
Cosmetic Act for emergency treatment
of known or suspected opioid overdose.
• Grants to Prevent Prescription
Drug/Opioid Overdose-Related Deaths
(PDO): The purpose of this program is
to support first responders and members
of other key community sectors to
administer a drug or device approved or
cleared under the Federal Food, Drug,
and Cosmetic Act (FD&C Act) for
emergency reversal of known or
suspected opioid overdose. Recipients
will train and provide resources to first
responders and members of other key
community sectors at the state, tribal,
and local levels on carrying and
administering a drug or device approved
or cleared under the FD&C Act for
emergency treatment of known or
suspected opioid overdose.
• Improving Access to Overdose
Treatment (ODTA): The purpose of this
program is to expand access to naloxone
and other Food and Drug
Administration (FDA) approved
overdose reversal medications for
emergency treatment of known or
suspected opioid overdose. The
recipients will collaborate with other
prescribers at the community level to
implement trainings on policies,
procedures, and models of care for
prescribing, co-prescribing, and
expanding access to naloxone and other
FDA-approved overdose reversal
medications to the specified population
of focus (i.e., rural or urban). With this
program SAMHSA aims to expand
access to naloxone and other FDA
approved overdose reversal medications
for emergency treatment of known or
suspected opioid overdose.
Grant compliance monitoring: All
SAMHSA awards require grantees to
submit performance and progress
reports through the electronic Research
E:\FR\FM\14MRN1.SGM
14MRN1
18654
Federal Register / Vol. 89, No. 51 / Thursday, March 14, 2024 / Notices
Administration (eRA) Commons, an
end-to-end Grants Management system.
The frequency and program-specific
instructions for preparation and
submission of these reports are
identified in the terms and conditions
found in the Notice of Award. CSAP
discretionary grant compliance
monitoring will be conducted through
the submission of the Programmatic
Progress Report (PPR). The PPR contains
fields for grantees to enter information
on activities and accomplishments that
occurred during the reporting period
based on identified goals and objectives.
It also contains fields for grantees to
share evaluation updates and outcomes
as well as planned activities for the
upcoming reporting period as well as
any challenges that grantees have
experienced.
The Center for Substance Abuse
Prevention Online Reporting Tool
(CORT) is comprised of two
components. The first provides fields
for grantees to enter annual goals for key
programmatic measures. The second
provides fields for reporting quarterly
progress toward achieving these goals.
CSAP intends to have grantees report
progress on a quarterly basis to allow for
consistent, periodic analyses which will
allow for the administration of technical
assistance supports when grantees are
falling behind in achieving these goals.
Quarterly reporting will also allow the
Center to review the overall progress of
grant programs. Program specific
instruments have been developed to
ensure optimal alignment with
individual grant requirements. These
instruments were developed based on
instruments approved in OMB 0930–
0391: Harm Reduction Grant Program
Annual Targets and Quarterly Progress
Reports.
Annualized Data Collection Burden
TABLE 1—BURDEN TABLE: ANNUALIZED BURDEN—ANNUAL TARGETS
Number of
respondents
Instrument
Responses per
respondent
Total
number of
responses
Hours per
response
Total
burden
hours
Average
hourly
wage1
Total
respondent
cost
STOP Act .....................................................
SPF–PFS .....................................................
FR CARA .....................................................
PDO .............................................................
ODTA ...........................................................
SPF–Rx ........................................................
202
315
87
18
8
27
1
1
1
1
1
1
202
315
87
18
8
27
0.5
0.5
0.5
0.5
0.5
0.5
101
157.5
43.5
9
4
13.5
$48.35
48.35
48.35
48.35
48.35
48.35
$4,883.35
7,615.125
2,103.225
435.15
193.4
652.725
Total (Annual) .......................................
657
..........................
657
..................
328.5
................
15,882.98
TABLE 2—BURDEN TABLE: CENTER FOR SUBSTANCE ABUSE PREVENTION ON-LINE REPORT TOOL (CORT)—QUARTERLY
PERFORMANCE ANNUALIZED BURDEN
Number of
respondents
Instrument
Responses per
respondent
Total
number of
responses
Hours per
response
Total
burden
hours
Average
hourly
wage 1
Total
respondent
cost
STOP Act .....................................................
SPF–PFS .....................................................
FR CARA .....................................................
PDO .............................................................
ODTA ...........................................................
SPF–Rx ........................................................
202
315
87
18
8
27
4
4
4
4
4
4
808
1,260
348
72
32
108
0.5
0.5
0.5
0.5
0.5
0.5
404
630
174
36
16
54
$48.35
48.35
48.35
48.35
48.35
48.35
$19,533.40
30,460.50
8,412.90
1,740.60
773.60
2,610.90
Total (Annual) .......................................
657
..........................
2,628
..................
1,314
................
63,531.90
1 Grantee Project Director or Evaluator hourly wage is based on the mean hourly wage for state government managers, as reported in the
2022 Occupational Employment (OES) by the Bureau of Labor Statistics (BLS) found at https://www.bls.gov/oes/current/naics4_999200.htm#110000 Accessed on December 13, 2023.
TABLE 3—ANNUALIZED BURDEN TABLE: CSAP’S GRANT PROGRAMMATIC PROGRESS REPORT
Number of
respondents
ddrumheller on DSK120RN23PROD with NOTICES1
CSAP grant program
Responses per
respondent
Total
number of
responses
Hours per
response
Total
burden
hours
Average
hourly
wage 1
Total
respondent
cost
SPF–PFS .....................................................
STOP Act .....................................................
SPF Rx .........................................................
FR CARA .....................................................
PDO .............................................................
ODTA ...........................................................
315
202
27
87
18
8
1
1
1
1
1
1
315
202
27
87
18
8
3
3
3
3
3
3
945.0
606.0
81.0
261.0
54.0
24.0
$48.35
48.35
48.35
48.35
48.35
48.35
$45,690.75
29,300.10
3,916.35
12,619.35
2,610.90
1,160.40
Total (Annual) .......................................
657
..........................
..................
..................
1,971.00
................
95,297.85
VerDate Sep<11>2014
16:47 Mar 13, 2024
Jkt 262001
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
E:\FR\FM\14MRN1.SGM
14MRN1
Federal Register / Vol. 89, No. 51 / Thursday, March 14, 2024 / Notices
Send comments to Carlos Graham,
SAMHSA Reports Clearance Officer,
5600 Fisher Lane, Room 15E57A,
Rockville, MD 20852 OR email him a
copy at carlos.graham@samhsa.hhs.gov.
Written comments should be received
by May 13, 2024.
Alicia Broadus,
Public Health Advisor.
[FR Doc. 2024–05444 Filed 3–13–24; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities Comment Request
ddrumheller on DSK120RN23PROD with NOTICES1
In compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer at (240) 276–
0361.
Comments are invited on: (a) whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: Drug and Alcohol
Warning Network (DAWN) (OMB No.
0930–0078)—Reinstatement With
Change
Under the Public Health Service Act
(42 U.S.C. 290aa–4), SAMHSA is
authorized to collect data on the number
of individuals admitted to the
emergency rooms of hospitals as a result
of the abuse of alcohol or other drugs.
DAWN is a nationwide public health
surveillance system to improve hospital
emergency department (ED) monitoring
of substance use-related visits. It
captures data on ED visits related to
recent substance use and misuse
VerDate Sep<11>2014
16:47 Mar 13, 2024
Jkt 262001
directly from the electronic health
records (EHR) of participating hospitals.
The new DAWN helps SAMHSA and
public health professionals, clinicians,
and policymakers respond effectively to
the opioid and substance misuse crisis
in the United States.
SAMHSA is requesting OMB approval
of reinstatement with change of the
DAWN data collections, to include
following changes:
• Revise the data collection title to
‘‘Drug and Alcohol Warning Network’’,
replacing existing ‘abuse’ term and
including ‘‘alcohol’’ in the title.
• Remove drug-related death
investigation records review component
administered by state medical
examiners (MEs) and individual
medical examiners/coroners (ME/Cs).
• Revise data collection procedures
where participating hospitals can
choose the direct chart review option (at
the contractor’s operation center, homebased abstraction or on site at the
hospital). Hospitals will also have the
opportunity to select the machine
learning with natural language
processing (ML with NLP) option. The
option for hospitals to use their own
staff to abstract DAWN data as they did
in the legacy DAWN is no longer
offered.
• Revise the hospital selection design
of the ED component to a hybrid system
that combines sentinel hospitals and
probability-based selection of hospitals
from high priority suburban/rural areas
and from the remaining areas in the
United States.
• Change the reporting and
publication schedule to further increase
the timeliness of the new DAWN data
availability and delivery to SAMHSA.
The new DAWN data are collected on
an ongoing basis and could be available
to SAMHSA on demand. The new
DAWN data are delivered to SAMHSA
and available for analysis at a more
frequent intervals than the legacy
DAWN.
• Propose following changes to the
ED Case Report Form:
Æ Add ‘‘Center for Behavioral Health
Statistics and Quality’’ to specify the
center responsible for DAWN data
collection.
Æ Revise the data collection title to
‘‘Drug and Alcohol Warning Network’’
from ‘‘Drug Abuse Warning Network.’’
Æ Replace prior ‘‘Facility’’ data field
title with ‘‘Hospital Emergency
Department ID’’ to provide more precise
description and ID number of the
DAWN participating hospitals.
Æ Q3 ‘‘Age’’: replace prior option of
‘‘less than 1 year’’ with two detailed
options of ‘‘4 weeks (28 days) or
younger’’ and ‘‘Between 4 weeks and
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
18655
one year old (>4 weeks, <1 year)’’ to
enable new identification of neonatal
substance issues.
Æ Q4 ‘‘County of Residence’’: revise
data field title from prior ‘‘patient’s
home zip code’’ and add more accurate
description on what data to be collected
and clarify the purpose of data
collection. Add new ‘‘Unable to
determine county’’ option to improve
data accuracy and account for
geographical variation.
Æ Q6 ‘‘Gender Identity’’ and Q7
‘‘Sexual Orientation’’: added to provide
inclusive measures and to align with
SAMHSA’s efforts in enhancing
behavioral health equities among
diverse populations.
Æ Q8 ‘‘Ethnicity’’ and Q9 ‘‘Race’’:
revise prior data field ‘‘Race/Ethnicity’’
to align with OMB 1997 Standards for
Maintaining, Collecting, And Presenting
Federal Data on Race and Ethnicity
(Statistical Policy Directive No. 15) and
to improve data accuracy and
comprehensiveness.
Æ Q10 ‘‘Case Description’’: replace
the word ‘‘drug(s)’’ with ‘‘substance(s)’’
to clarify that the DAWN collects data
on all substances including alcohol.
Add new instruction language of ‘‘Do
not include information that could
identify the patient or hospital’’ to
provide clear instruction and specify the
importance of patient and hospital
privacy protection.
Æ Q11 ‘‘Substance(s) Involved and
Route of Administration’’: add two new
options of ‘‘transdermal’’ and ‘‘vaped’’
to improve the comprehensiveness of
the list on how substance is
administered by the patient. Remove
‘‘Mark if confirmed by toxicology test’’
and ‘‘alcohol involved?’’
Æ Q12 ‘‘Diagnosis’’: change the
question order and move the data field
after Q11. Revise prior instruction of
‘‘list up to 4 diagnoses’’ to ‘‘list all
diagnoses’’ to enhances new DAWN’s
ability to identify novel drug, drug
trends, and drug outbreaks.
Æ Q13 ‘‘Type of Case’’: remove
instruction language of ‘‘using the
decision tree.’’ Revise the existing
option of ‘‘seeking detox’’ to ‘‘seeking
detox and/or substance abuse treatment
only’’ and remove age restriction for
‘‘Alcohol only’’ option to include cases
involving alcohol as the only substance
of all ages.
Æ Q14, Q15, and Q16 ‘‘Was naloxone/
buprenorphine/Methadone
administered to the patient in the ED’’:
added to capture new data on the
implementation of medication-assisted
treatment for opioid use disorder in the
emergency department setting and
understand why buprenorphine and
methadone is administered.
E:\FR\FM\14MRN1.SGM
14MRN1
]]>Agencies
[Federal Register Volume 89, Number 51 (Thursday, March 14, 2024)]
[Notices]
[Pages 18653-18655]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-05444]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and Mental Health Services
Administration (SAMHSA) will publish a summary of information
collection requests under OMB review, in compliance with the Paperwork
Reduction Act (44 U.S.C. Chapter 35). To request a copy of these
documents, call the SAMHSA Reports Clearance Officer on (240) 276-0361.
Proposed Project: New: The Center for Substance Abuse Prevention Online
Reporting Tool and Grant Programmatic Progress Report To Replace
Division of State Programs--Management Reporting Tool (DSP-MRT) (OMB
No. 0930-0354)
The Substance Abuse and Mental Health Services Administration's
(SAMHSA), Center for Substance Abuse Prevention (CSAP) is requesting
approval from the Office of Management and Budget (OMB) to monitor CSAP
discretionary grant programs through administration of a suite of data
collection instruments for grant compliance and programmatic
performance monitoring. This package describes the data collection
activities and proposed instruments. Grant compliance monitoring will
be conducted via a single data collection instrument to be completed by
all CSAP discretionary grant recipients. Programmatic performance
monitoring will be conducted via a suite of data collection instruments
with each instrument tailored to a specific CSAP discretionary program.
This request for data collection will replace OMB No. 0930-0354:
Division of State Programs--Management Reporting Tool.
CSAP intends to monitor six grant programs through this data
collection effort:
Strategic Prevention Framework--Partnerships for Success
(SPF-PFS): The purpose of the SPF-PFS program is to help reduce the
onset and progression of substance misuse and its related problems by
supporting the development and delivery of state and community
substance misuse prevention and mental health promotion services. This
program is intended to promote substance use prevention throughout a
state jurisdiction for individuals and families by building and
expanding the capacity of local community prevention providers to
implement evidence-based programs. In addition, the program is intended
to expand and strengthen the capacity of local community prevention
providers to implement evidence-based prevention programs. With this
program, SAMHSA aims to strengthen state and community level prevention
capacity to identify and address local substance use prevention
concerns, such as underage drinking, marijuana, tobacco, electronic
cigarettes, opioids, methamphetamine, and heroin.
Sober Truth on Preventing Underage Drinking (STOP Act):
The purpose of this program is to prevent and reduce alcohol use among
youth and young adults ages 12-20 in communities throughout the United
States through evidence-based screening, programs and curricula, brief
intervention strategies, consistent policy enforcement, and
environmental changes that limit underage access to alcohol as
authorized by 942 U.S.C. 290bb-25b. The program aims to: (1) address
norms regarding alcohol use by youth, (2) reduce opportunities for
underage drinking, (3) create changes in underage drinking enforcement
efforts, (4) address penalties for underage use, and/or (5) reduce
negative consequences associated with underage drinking.
Strategic Prevention Framework for Prescription Drugs (SPF
Rx): The purpose of the SPF Rx grant program is to provide resources to
help prevent and address prescription drug misuse within a State or
locality. The program is designed to raise awareness about the dangers
of sharing medications as well as the risks of fake or counterfeit
pills purchased over social media or other unknown sources, and work
with pharmaceutical and medical communities on the risks of
overprescribing. Whether addressed at the state level or by an informed
community-based organization, the SPF Rx program will raise community
awareness and bring prescription substance misuse prevention activities
and education to schools, communities, parents, prescribers, and their
patients. In addition, grant recipients will be required to track
reductions in opioid related overdoses and incorporate relevant
prescription and overdose data into strategic planning and future
programming.
First Responders--Comprehensive Addiction and Recovery Act
(FR CARA): The purpose of this program is to allow first responders and
members of other key community sectors to administer a drug or device
approved or cleared under the Federal Food, Drug, and Cosmetic Act for
emergency treatment of known or suspected opioid overdose.
Grants to Prevent Prescription Drug/Opioid Overdose-
Related Deaths (PDO): The purpose of this program is to support first
responders and members of other key community sectors to administer a
drug or device approved or cleared under the Federal Food, Drug, and
Cosmetic Act (FD&C Act) for emergency reversal of known or suspected
opioid overdose. Recipients will train and provide resources to first
responders and members of other key community sectors at the state,
tribal, and local levels on carrying and administering a drug or device
approved or cleared under the FD&C Act for emergency treatment of known
or suspected opioid overdose.
Improving Access to Overdose Treatment (ODTA): The purpose
of this program is to expand access to naloxone and other Food and Drug
Administration (FDA) approved overdose reversal medications for
emergency treatment of known or suspected opioid overdose. The
recipients will collaborate with other prescribers at the community
level to implement trainings on policies, procedures, and models of
care for prescribing, co-prescribing, and expanding access to naloxone
and other FDA-approved overdose reversal medications to the specified
population of focus (i.e., rural or urban). With this program SAMHSA
aims to expand access to naloxone and other FDA approved overdose
reversal medications for emergency treatment of known or suspected
opioid overdose.
Grant compliance monitoring: All SAMHSA awards require grantees to
submit performance and progress reports through the electronic Research
[[Page 18654]]
Administration (eRA) Commons, an end-to-end Grants Management system.
The frequency and program-specific instructions for preparation and
submission of these reports are identified in the terms and conditions
found in the Notice of Award. CSAP discretionary grant compliance
monitoring will be conducted through the submission of the Programmatic
Progress Report (PPR). The PPR contains fields for grantees to enter
information on activities and accomplishments that occurred during the
reporting period based on identified goals and objectives. It also
contains fields for grantees to share evaluation updates and outcomes
as well as planned activities for the upcoming reporting period as well
as any challenges that grantees have experienced.
The Center for Substance Abuse Prevention Online Reporting Tool
(CORT) is comprised of two components. The first provides fields for
grantees to enter annual goals for key programmatic measures. The
second provides fields for reporting quarterly progress toward
achieving these goals. CSAP intends to have grantees report progress on
a quarterly basis to allow for consistent, periodic analyses which will
allow for the administration of technical assistance supports when
grantees are falling behind in achieving these goals. Quarterly
reporting will also allow the Center to review the overall progress of
grant programs. Program specific instruments have been developed to
ensure optimal alignment with individual grant requirements. These
instruments were developed based on instruments approved in OMB 0930-
0391: Harm Reduction Grant Program Annual Targets and Quarterly
Progress Reports.
Annualized Data Collection Burden
Table 1--Burden Table: Annualized Burden--Annual Targets
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total Total Average Total
Instrument Number of Responses per number of Hours per burden hourly respondent
respondents respondent responses response hours wage\1\ cost
--------------------------------------------------------------------------------------------------------------------------------------------------------
STOP Act...................................................... 202 1 202 0.5 101 $48.35 $4,883.35
SPF-PFS....................................................... 315 1 315 0.5 157.5 48.35 7,615.125
FR CARA....................................................... 87 1 87 0.5 43.5 48.35 2,103.225
PDO........................................................... 18 1 18 0.5 9 48.35 435.15
ODTA.......................................................... 8 1 8 0.5 4 48.35 193.4
SPF-Rx........................................................ 27 1 27 0.5 13.5 48.35 652.725
-----------------------------------------------------------------------------------------
Total (Annual)............................................ 657 ............... 657 .......... 328.5 ......... 15,882.98
--------------------------------------------------------------------------------------------------------------------------------------------------------
Table 2--Burden Table: Center for Substance Abuse Prevention On-Line Report Tool (CORT)--Quarterly Performance Annualized Burden
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total Total Average Total
Instrument Number of Responses per number of Hours per burden hourly respondent
respondents respondent responses response hours wage \1\ cost
--------------------------------------------------------------------------------------------------------------------------------------------------------
STOP Act...................................................... 202 4 808 0.5 404 $48.35 $19,533.40
SPF-PFS....................................................... 315 4 1,260 0.5 630 48.35 30,460.50
FR CARA....................................................... 87 4 348 0.5 174 48.35 8,412.90
PDO........................................................... 18 4 72 0.5 36 48.35 1,740.60
ODTA.......................................................... 8 4 32 0.5 16 48.35 773.60
SPF-Rx........................................................ 27 4 108 0.5 54 48.35 2,610.90
-----------------------------------------------------------------------------------------
Total (Annual)............................................ 657 ............... 2,628 .......... 1,314 ......... 63,531.90
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ Grantee Project Director or Evaluator hourly wage is based on the mean hourly wage for state government managers, as reported in the 2022
Occupational Employment (OES) by the Bureau of Labor Statistics (BLS) found at https://www.bls.gov/oes/current/naics4_999200.htm#11-0000 Accessed on
December 13, 2023.
Table 3--Annualized Burden Table: CSAP's Grant Programmatic Progress Report
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total Total Average Total
CSAP grant program Number of Responses per number of Hours per burden hourly respondent
respondents respondent responses response hours wage \1\ cost
--------------------------------------------------------------------------------------------------------------------------------------------------------
SPF-PFS....................................................... 315 1 315 3 945.0 $48.35 $45,690.75
STOP Act...................................................... 202 1 202 3 606.0 48.35 29,300.10
SPF Rx........................................................ 27 1 27 3 81.0 48.35 3,916.35
FR CARA....................................................... 87 1 87 3 261.0 48.35 12,619.35
PDO........................................................... 18 1 18 3 54.0 48.35 2,610.90
ODTA.......................................................... 8 1 8 3 24.0 48.35 1,160.40
-----------------------------------------------------------------------------------------
Total (Annual)............................................ 657 ............... .......... .......... 1,971.00 ......... 95,297.85
--------------------------------------------------------------------------------------------------------------------------------------------------------
[[Page 18655]]
Send comments to Carlos Graham, SAMHSA Reports Clearance Officer,
5600 Fisher Lane, Room 15E57A, Rockville, MD 20852 OR email him a copy
at [email protected]. Written comments should be received by
May 13, 2024.
Alicia Broadus,
Public Health Advisor.
[FR Doc. 2024-05444 Filed 3-13-24; 8:45 am]
BILLING CODE 4162-20-P
